The National Institute for Health and Care Excellence (NICE) has recommended Immunocore’s Kimmtrak (tebentafusp) as the first ...

The pioneering new drug was found to increase average overall survival by almost five months compared to other standard ...

This is frequently diagnosed in dogs that were never spayed and the only type of cancer in dogs that has research showing ...

In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.